ReviewBreast cancer research and treatment2023

Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.

Miguel Martín et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.